

Supplementary material

An In Vitro Antimicrobial, Anticancer and Antioxidant Activity of *N*-[(2-Arylmethylthio)phenylsulfonyl]cinnamamide Derivatives

Anita Bułakowska ^{1,*,†}, Jarosław Sławiński ¹, Rafał Hałasa ^{2,†}, Anna Hering ³, Magdalena Gucwa ³, J. Renata Ochocka ³ and Justyna Stefanowicz-Hajduk ^{3,*}

¹ Department of Organic Chemistry, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdansk, Poland; jaroslaw@gumed.edu.pl

² Department of Pharmaceutical Microbiology, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdansk, Poland; rafal.halasa@gumed.edu.pl

³ Department of Biology and Pharmaceutical Botany, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdansk, Poland; anna.hering@gumed.edu.pl (A.H.); magdalena.gucwa@gumed.edu.pl (M.G.); jadwiga.ochocka@gumed.edu.pl (J.R.O.)

* Correspondence: bulanit@gumed.edu.pl (A.B.); justyna.stefanowicz-hajduk@gumed.edu.pl (J.S.-H.)

† These authors contributed equally to this work.

Tabele of contents

Appendix A:

Spectrum 1. ¹H NMR of compd **2** (500 MHz, DMSO-*d*₆).

Spectrum 2. ¹H NMR of compd **3** (500 MHz, DMSO-*d*₆).

Spectrum 3. ¹H NMR of compd **16a** (500 MHz, DMSO-*d*₆)

Spectrum 4. ¹H NMR of compd **16b** (500 MHz, DMSO-*d*₆).

Spectrum 5. ¹H NMR of compd **16c** (500 MHz, DMSO-*d*₆).

Spectrum 6. ¹H NMR of compd **16d** (500 MHz, DMSO-*d*₆)

Spectrum 7. ¹H NMR of compd **16e** (500 MHz, DMSO-*d*₆).

Spectrum 8. ¹³C NMR of compd **16e** (125 MHz, DMSO-*d*₆).

Spectrum 9. ¹H NMR of compd **16f** (500 MHz, DMSO-*d*₆).

Spectrum 10. ¹³C NMR of compd **16f** (125 MHz, DMSO-*d*₆).

Spectrum 11. ¹H NMR of compd **17a** (500 MHz, DMSO-*d*₆).

Spectrum 12. ¹³C NMR of compd **17a** (125 MHz, DMSO-*d*₆).

Spectrum 13. ¹H NMR of compd **17b** (500 MHz, DMSO-*d*₆).


Spectrum 14. ¹³C NMR of compd **17b** (125 MHz, DMSO-*d*₆).


Spectrum 15. ^1H NMR of compd **17c** (500 MHz, $\text{DMSO-}d_6$).

Spectrum 16. ^{13}C NMR of compd **17c** (125 MHz, $\text{DMSO-}d_6$).


Spectrum 17. ^1H NMR of compd **17d** (500 MHz, $\text{DMSO-}d_6$).


Spectrum 1. ^1H NMR of compd **2** (500 MHz, $\text{DMSO}-d_6$).






Spectrum 2. ^1H NMR of compd 3 (500 MHz, $\text{DMSO}-d_6$).







Spectrum 4. ¹H NMR of compd **16b** (500 MHz, DMSO-*d*₆).




Spectrum 5. ¹H NMR of compd **16c** (500 MHz, DMSO-*d*₆).




Spectrum 6. ¹H NMR of compd **16d** (500 MHz, DMSO-*d*₆).




Spectrum 7. ¹H NMR of compd **16e** (500 MHz, DMSO-*d*₆).




Spectrum 8. ^{13}C NMR of compd **16e** (125 MHz, $\text{DMSO}-d_6$).




Spectrum 9. ¹H NMR of compd 16f (500 MHz, DMSO-*d*₆).




Spectrum 10. ^{13}C NMR of compd **16f** (125 MHz, $\text{DMSO}-d_6$).




Spectrum 11. ¹H NMR of compd 17a (500 MHz, DMSO-*d*₆).




Spectrum 12. ^{13}C NMR of compd 17a (125 MHz, $\text{DMSO}-d_6$).




Spectrum 13. ¹H NMR of compd 17b (500 MHz, DMSO-*d*₆).




Spectrum 14. ^{13}C NMR of compd **17b** (125 MHz, $\text{DMSO}-d_6$).



Spectrum 15. ^1H NMR of compd 17c (500 MHz, $\text{DMSO}-d_6$).



Spectrum 16. ^{13}C NMR of compd **17c** (125 MHz, $\text{DMSO}-d_6$).



Spectrum 17. ¹H NMR of compd **17d** (500 MHz, DMSO-*d*₆).

Appendix B:

Table S1. Maximum absorbance of the analyzed compounds in 10% DMSO/methanol (*v/v*) and in cell culture medium in 0 h and after 96 h.

	16a	16b	16c	16d	16e	16f	17a	17b	17c	17d
In 10% DMSO/methanol (<i>v/v</i>)	315 ± 1	314 ± 0	315 ± 1	304 ± 1	324 ± 0	310 ± 0	315 ± 1	309 ± 1	314 ± 0	324 ± 0
In cell culture medium <i>t</i> ₀	300 ± 0	299 ± 1	300 ± 0	296 ± 0	307 ± 1	306 ± 3	300 ± 0	298 ± 0	300 ± 0	305 ± 1
In cell culture medium <i>t</i> ₉₆	300 ± 0	300 ± 0	303 ± 1	297 ± 1	306 ± 0	305 ± 2	300 ± 0	298 ± 0	300 ± 0	306 ± 0

The resulting λ_{max} are obtained from three replications and are presented as mean values with the standard deviation ($\pm$ SD). The concentration of the tested compounds in cell culture medium was 25% (*v/v*).

Table S2. Minimum inhibitory concentration [$\mu\text{g/mL}$] of the cinnamic acid derivatives on MRSA strains.

[illegible]

[illegible]

Table S3. Minimum inhibitory concentration [$\mu\text{g/mL}$] of the cinnamic acid derivatives on MRCNS strains.

Compd	MIC [$\mu\text{g/mL}$]		
	MRSE13199	MRCNS16248	MRCNS15554
16a	1 $\pm$ 0.12	2 $\pm$ 0.29	2 $\pm$ 0.12
16b	1 $\pm$ 0.12	1 $\pm$ 0.12	2 $\pm$ 0.29
16c	1 $\pm$ 0.12	2 $\pm$ 0.29	2 $\pm$ 0.12
16d	1 $\pm$ 0.12	2 $\pm$ 0.29	1 $\pm$ 0.12
16e	1 $\pm$ 0.12	2 $\pm$ 0.29	2 $\pm$ 0.12
16f	1 $\pm$ 0.06	1 $\pm$ 0.12	1 $\pm$ 0.12
17a	1 $\pm$ 0.12	2 $\pm$ 0.29	2 $\pm$ 0.12
17b	2 $\pm$ 0.29	4 $\pm$ 0.12	4 $\pm$ 0.06
17c	1 $\pm$ 0.12	2 $\pm$ 0.12	1 $\pm$ 0.12
17d	2 $\pm$ 0.29	4 $\pm$ 0.12	4 $\pm$ 0.17
Co-trimoxazole	<1/0.2	<1/0.2	<1/0.2

